EUVIMEDDescoperă EUVIMED
Open access

Suppression of dystroglycan function accompanies pancreatic acinar‐to‐ductal metaplasia and favours dysplasia development

Ge Huang, Luke Ternes, Christian Lanciault, Kevin MacPherson-Hawthorne, Young Hwan Chang iD, Rosalie C Sears iD, John L Muschler iD

The Journal of Pathology · 2024

DOI: 10.1002/path.6356 ↗

At a glance

Journal article in The Journal of Pathology, 2024. Written by Ge Huang and 6 co-authors. Institution: Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA. Major MEDLINE topics: Metaplasia, Dystroglycans, Pancreatic Neoplasms, Precancerous Conditions. Cited 3 times so far (Crossref); 54 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, Brendon Colson Center for Pancreatic Care, NIH HHS.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

The basement membrane (BM) is among the predominant microenvironmental factors of normal epithelia and of precancerous epithelial lesions. Evidence suggests that the BM functions not only as a barrier to tumour invasion but also as an active tumour‐suppressing signalling substrate during premalignancy. However, the molecular foundations of such mechanisms have not been elucidated. Here we explore potential tumour‐suppressing functions of the BM during precancer evolution, focusing on the expression and function of the extracellular matrix receptor dystroglycan in the pancreas and pancreatic disease. We show that the dystroglycan protein is highly expressed in the acinar compartment of the normal pancreas but lower in the ductal compartment. Moreover, there is a strong suppression of dystroglycan protein expression with acinar‐to‐ductal metaplasia in chronic pancreatitis and in all stages of pancreatic precancer and cancer evolution, from acinar‐to‐ductal metaplasia to dysplasia to adenocarcinoma. The conditional knockout of dystroglycan in the murine pancreas produced little evidence of developmental or functional deficiency. However, conditional deletion of dystroglycan expression in the context of oncogenic Kras expression led to a clear acceleration of pancreatic disease evolution, including accelerated dysplasia development and decreased survival. These data establish dystroglycan as a suppressor of pancreatic dysplasia development and one that is muted in chronic pancreatitis and at the earliest stages of oncogene‐induced transformation. We conclude that dystroglycan is an important mediator of the tumour‐suppressing functions of the BM during precancer evolution and that reduced dystroglycan function increases cancer risk, highlighting the dynamics of cell–BM interactions as important determinants of early cancer progression. © 2024 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

MetaplasiaDystroglycansPancreatic NeoplasmsPrecancerous ConditionsPancreatic DuctsAnimalsHumansAcinar CellsBasement MembraneMice, KnockoutPancreatitis, ChronicProto-Oncogene Proteins p21(ras)MiceCarcinoma, Pancreatic DuctalPancreasDisease ProgressionDisease Models, Animal

Author keywords

basement membranedysplasiaextracellular matrixprecancer

Substances

DystroglycansProto-Oncogene Proteins p21(ras)Hras protein, mouse

Authors and institutions

  • Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Providence Regional Pathology, Portland, OR, USA.
  • Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
  • Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.

ORCID profiles: Young Hwan Chang, Rosalie C Sears, John L Muschler

Funding

  • NCI NIH HHS
  • Brendon Colson Center for Pancreatic Care
  • NIH HHS
  • National Cancer Institute Cancer Center
  • National Institutes of Health

Cite

APA

Huang, G., Ternes, L., Lanciault, C., MacPherson-Hawthorne, K., Chang, Y. H., Sears, R. C., & Muschler, J. L. (2024). Suppression of dystroglycan function accompanies pancreatic acinar‐to‐ductal metaplasia and favours dysplasia development. The Journal of Pathology. https://doi.org/10.1002/path.6356

Vancouver

Huang G, Ternes L, Lanciault C, MacPherson-Hawthorne K, Chang YH, Sears RC, et al. Suppression of dystroglycan function accompanies pancreatic acinar‐to‐ductal metaplasia and favours dysplasia development. The Journal of Pathology. 2024. doi:10.1002/path.6356

BibTeX
@article{Huang2024,
  author = {Huang, Ge and Ternes, Luke and Lanciault, Christian and MacPherson-Hawthorne, Kevin and Chang, Young Hwan and Sears, Rosalie C and Muschler, John L},
  title = {Suppression of dystroglycan function accompanies pancreatic acinar‐to‐ductal metaplasia and favours dysplasia development},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6356}
}
Start for free →